Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 


Cambridge Healthtech Institute’s Third Annual

New Frontiers in CRISPR-based Gene Editing

Developing Faster, Better Ways to Precisely and Efficiently Edit Genesy

February 23-24, 2017 | Moscone South Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

 

Gene editing has very rapidly established its importance as a research/screening tool in drug discovery, and promises its utility downstream in drug development, cell therapy and bioprocessing, as well. Cambridge Healthtech Institute’s third annual symposium on New Frontiers in CRISPR-based Gene Editing will bring together experts from all aspects of basic science and clinical research to talk about the recent progress made in gene editing and it’s growing applications. Knowing the strengths and limitations, how does one decide when to use the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, as opposed to alternate gene editing systems? What is being done to overcome some of the inherent challenges in design, delivery and off-target effects, associated with CRISPR and some of its alternatives that are being developed? Experts from pharma/biotech, academic and government labs will share their experiences leveraging the utility of CRISPR-based gene editing for diverse applications including, creating cell lines and knock-out models, for functional screening, cellular pathway visualization, and for therapeutics.

Who should attend: Students, Post-docs, Lab Technicians, Managers, Scientists, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Pathway Analysis, Target Identification and Validation, Functional Screening, Biomarker Discovery, Translational and Clinical Research, and Gene/Cell Therapy.

Topics will include, but are not limited to:

  • Understanding CRISPR biology
  • Growing alternatives to CRISPR and Cas9
  • Comparing gene editing tools: CRISPRs, TALENs, ZFNs and more
  • Designing enhanced specificity and efficacy in editing
  • Engineering precision gene editing
  • Creating relevant cell lines and knock-out models for disease modeling
  • Gene editing using induced pluripotent stem cells
  • Tackling challenges with off-target effects
  • Streamlining gene editing for therapeutic applications
  • Exploring uses in cell and gene therapy

If you would like to submit a proposal to give a presentation at this meeting, please visit click here.

The deadline for submission is July 25, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com